Close Menu
September 15, 2020
Sponsored by
Lexogen

Multi-omics in Clinical Cancer Diagnostics: The Importance of RNA-Seq

Genome Webinar

Professor of Cancer Genetics & Surgery, Institute of Cancer and Genomic Sciences
University of Birmingham

Senior Manager of Scientific Affairs,
Lexogen

Colorectal cancer is the third most frequently diagnosed cancer after lung and breast cancer and, unlike these agents, has relatively few stratified molecular targets for therapy due to the complex, heterogenous nature of the disease.

In this webinar, Andrew Beggs of the University of Birmingham will discuss a project that performed stratified analysis of patients as a pre-pilot for the 100,000 Genomes project. His team performed whole-genome sequencing on fresh samples and, as proof of principle, 3’ RNA-seq on matched formalin-fixed, paraffin-embedded samples.

Dr. Beggs will demonstrate that by combining WGS and RNA-seq, many interesting insights can be gained into the underlying disease processes in colorectal cancer, allowing identification of new targets for therapy and disease stratification.

Dr. Lukas Paul, Senior Manager of Scientific Affairs  will talk discuss the acceleration of gene expression profiling projects with the massive multiplexing of 3’ mRNA-Seq libraries.

Sponsored by
Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.